De, P., Sun, Y., Carlson, J. H., Friedman, L. S., Leyland-Jones, B. R., & Dey, N. (2014). Doubling Down on the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model beyond BRCA-ness. Neoplasia Press Inc.
Citação norma ChicagoDe, Pradip, Yuling Sun, Jennifer H. Carlson, Lori S. Friedman, Brian R. Leyland-Jones, and Nandini Dey. Doubling Down On the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model Beyond BRCA-ness. Neoplasia Press Inc, 2014.
ציטוט MLADe, Pradip, et al. Doubling Down On the PI3K-AKT-mTOR Pathway Enhances the Antitumor Efficacy of PARP Inhibitor in Triple Negative Breast Cancer Model Beyond BRCA-ness. Neoplasia Press Inc, 2014.